1. We studied the effect of a new @entity1808 type 1 ( @entity1129 (1)) receptor antagonist, @entity15632 ( @entity9885 ), on the fibrogenic responses in @entity35 hepatic stellate cells (HSCs) and liver fibrogenesis. 2. @entity9885 (1 mg kg(-1) per day) was orally administered to fibrotic @entity35 , induced by bile duct ligation. Liver @entity720 content, the mRNA expression of collagen alpha1(I) and @entity1918 ( @entity1918 ), and plasma levels of @entity1810 ( @entity1810 ) were significantly reduced by @entity9885 treatment, suggesting that @entity9885 improved @entity1575 . Interestingly, @entity1129 (1) receptors were found to be expressed in @entity1918 -positive cells in the fibrotic area of livers in bile duct-ligated @entity35 by immunohistochemical analysis. @entity9885 treatment reduced the number of these cells. 3. In vitro experiments showed that @entity1808 ( @entity1808 ) treatment induced proliferation and collagen synthesis, and upregulated the profibrogenic cytokines, @entity1810 and @entity2528 ( @entity2528 ), in @entity35 primary HSCs. @entity9885 blocked all these effects of @entity1808 . 4. Based on these results, since activated HSCs were found to express @entity1129 (1) receptors and @entity1808 is thought to play an important role in the pathogenesis of @entity1575 by binding to these receptors, @entity9885 may act as a potent antifibrotic drug to suppress the proliferation, collagen synthesis and the expression of profibrogenic cytokines in activated HSCs by blocking these receptors.

An angiotensin II type 1 receptor antagonist, @entity15632 , improves experimental XXXX by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.

@entity1575 :: ('MESH:D008103', 'Disease') :: ['liver fibrosis'] @entity1808 :: ('24179(Tax:10116)', 'Gene') :: ['Ang II', 'angiotensin II'] @entity15632 :: ('MESH:C097933', 'Chemical') :: ['olmesartan medoxomil'] @entity1918 :: ('25365(Tax:10116)', 'Gene') :: ['alpha-SMA', 'alpha-smooth muscle actin'] @entity9885 :: ('MESH:C437965', 'Chemical') :: ['olmesartan', 'Olmesartan'] @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline'] @entity1129 :: ('MESH:D001260', 'Disease') :: ['AT'] @entity1810 :: ('59086(Tax:10116)', 'Gene') :: ['TGF-beta1', 'transforming growth factor-beta1'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity2528 :: ('64032(Tax:10116)', 'Gene') :: ['CTGF', 'connective tissue growth factor']
@entity1575 :: (MESH:D008103,Disease) :: ['liver fibrosis']
